Table I.
Association between MYH9 expression and clinicopathological variables using the χ2 or Fisher's exact test.
| MYH9 | |||||
|---|---|---|---|---|---|
| Characteristic | Total, n (%) | No or low expression | Moderate or strong expression | χ2 test P-value | Fisher's exact test P-value |
| Age, years | |||||
| ≤50 | 122 (46.04) | 39 | 83 | 0.1049 | |
| >50 | 143 (53.96) | 33 | 110 | ||
| Histological type | |||||
| Serous adenocarcinoma | 160 (69.87) | 38 | 122 | 0.0684 | |
| Mucoid adenocarcinoma | 13 (5.68) | 5 | 8 | ||
| Endometrial adenocarcinoma | 38 (16.59) | 13 | 25 | ||
| Clear cell carcinoma | 18 (7.86) | 9 | 9 | ||
| FIGO stage | |||||
| I | 43 (16.23) | 17 | 26 | 0.0011 | |
| II | 27 (10.19) | 14 | 13 | ||
| III | 156 (58.87) | 35 | 121 | ||
| IV | 39 (14.71) | 6 | 33 | ||
| Lymph node metastasis | |||||
| No | 61 (58.10) | 30 | 31 | 0.0059 | |
| Yes | 44 (41.90) | 10 | 34 | ||
| Intraperitoneal metastasis | |||||
| No | 87 (32.95) | 39 | 48 | <0.0001 | |
| Yes | 177 (67.05) | 33 | 144 | ||
| Intestinal metastasis | |||||
| No | 135 (51.14) | 39 | 96 | 0.5464 | |
| Yes | 129 (48.86) | 33 | 96 | ||
| Vital status | |||||
| Alive | 111 (57.81) | 46 | 65 | <0.0001 | |
| Dead | 81 (42.19) | 12 | 69 | ||
| Intraperitoneal recurrence | |||||
| No | 186 (71.81) | 60 | 126 | 0.0053 | |
| Yes | 73 (28.19) | 11 | 62 | ||
| Distant recurrence | |||||
| No | 222 (85.71) | 64 | 158 | 0.2109 | |
| Yes | 37 (14.29) | 7 | 30 | ||
| Residual tumor size (cm) | |||||
| ≤1 | 241 (90.94) | 70 | 171 | 0.0296 | 0.0302 |
| >1 | 24 (9.06) | 2 | 22 | ||
| Differentiation grade | |||||
| G1/G2 | 96 (39.51) | 28 | 68 | 0.4184 | |
| G3 | 147 (60.49) | 36 | 111 | ||
| Neoadjuvant chemotherapy | |||||
| No | 234 (88.30) | 67 | 167 | 0.1414 | 0.1967 |
| Yes | 31 (11.70) | 5 | 26 | ||
| Postoperative chemotherapy | |||||
| No | 8 (3.05) | 1 | 7 | 0.4520 | |
| Yes | 254 (96.95) | 71 | 183 | ||
| Platinum resistance | |||||
| No | 255 (97.33) | 70 | 185 | >0.05 | |
| Yes | 7 (2.67) | 2 | 5 | ||
| Hyperthermic intraperitoneal chemotherapy | |||||
| No | 240 (90.91) | 65 | 175 | 0.8270 | |
| Yes | 24 (9.09) | 7 | 17 | ||
| Ascites with tumor cells (+) | |||||
| No | 56 (50.91) | 24 | 32 | 0.0058 | |
| Yes | 54 (49.09) | 10 | 44 | ||
| Cytoreductive surgery | |||||
| No | 9 (3.42) | 1 | 8 | 0.2655 | 0.4515 |
| Yes | 254 (96.58) | 71 | 183 | ||
| CA125 (U/ml) | |||||
| ≤35 | 32 (12.65) | 11 | 21 | 0.3060 | |
| >35 | 221 (87.35) | 57 | 164 | ||
| CA72-4 (U/ml) | |||||
| ≤7 | 99 (45.83) | 30 | 69 | 0.4459 | |
| >7 | 117 (54.17) | 30 | 87 | ||
| CA153 (U/ml) | |||||
| ≤25 | 31 (32.29) | 6 | 25 | 0.5664 | |
| >25 | 65 (67.71) | 16 | 49 | ||
| AFP (U/ml) | |||||
| ≤25 | 209 (99.05) | 59 | 150 | >0.05 | |
| >25 | 2 (0.95) | 0 | 2 | ||
| CEA (U/ml) | |||||
| ≤5.0 | 189 (88.32) | 54 | 135 | 0.9526 | |
| >5.0 | 25 (11.68) | 7 | 18 | ||
| HE4 (pmol/l) | |||||
| ≤140 | 45 (34.35) | 16 | 29 | 0.6301 | |
| >140 | 86 (65.65) | 27 | 59 | ||
MYH9, myosin 9; FIGO, International Federation of Gynecology and Obstetrics. AFP, α-fetoprotein; CEA, carcinoembryonic antigen; HE4, human epididymis protein 4.